Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $311,104 - $359,209
-1,175 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$258.66 - $342.55 $303,925 - $402,496
1,175 New
1,175 $314,000
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $333,987 - $374,599
-1,536 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $43,419 - $47,860
198 Added 14.8%
1,536 $359,000
Q1 2019

May 13, 2019

SELL
$216.71 - $338.96 $1,950 - $3,050
-9 Reduced 0.67%
1,338 $316,000
Q4 2018

Feb 13, 2019

BUY
$278.5 - $352.75 $375,139 - $475,154
1,347 New
1,347 $405,000
Q1 2018

May 15, 2018

SELL
$260.13 - $367.91 $247,643 - $350,250
-952 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $22,150 - $24,809
72 Added 8.18%
952 $303,000
Q3 2017

Nov 14, 2017

BUY
$281.15 - $329.69 $247,411 - $290,127
880
880 $276,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $23B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Bienville Capital Management, LLC Portfolio

Follow Bienville Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bienville Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bienville Capital Management, LLC with notifications on news.